Henlius | 复宏汉霖 Employee Directory
Biotechnology ResearchShanghai, China501-1000 Employees
Henlius is a Shanghai-based biopharmaceutical company that develops, manufactures, and distributes oncology therapies. Drawing on experience across the pharmaceutical industry, its team works to deliver treatments that are both clinically effective and more affordable for patients in about 60 countries. The company focuses on oncology and other diseases with the aim of helping people regain healthy lives. Through its development and manufacturing activities, Henlius supports a growing portfolio in biotechnology. In April 2024, Henlius and Organon announced positive results from a phase 3 trial of HLX14, a denosumab biosimilar to Prolia and Xgeva, which met its primary endpoints. The same announcement described a license and supply agreement granting Organon exclusive commercialization rights to two denosumab biosimilar candidates. These developments reflect the company’s ongoing collaboration with global partners to advance oncology biosimilars.